Biomerica (BMRA) Long-Term Deferred Tax (2011 - 2023)

Biomerica (BMRA) posted Long-Term Deferred Tax of $8.1 million for Q1 2023, up 4.39% sequentially from $7.7 million in Q4 2022.

Biomerica (BMRA) Long-Term Deferred Tax (2011 - 2023) Analysis & Trends

Biomerica has reported Long-Term Deferred Tax for 11 years, with the latest figure at $8.1 million in Q1 2023.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $8.1 million in Q1 2023, while the trailing twelve-month figure through Feb 2023 was $8.1 million (changed N/A YoY) and the FY2022 annual result came in at $7.0 million, changed N/A from the prior year.
Long-Term Deferred Tax advanced to $8.1 million in Q1 2023 per BMRA's latest filing, from $7.7 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $8.1 million in Q1 2023 and troughed at $10000.0 in Q1 2019.
A 3-year average of $6.0 million and a median of $7.4 million in 2022 frame the typical range for Long-Term Deferred Tax.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	202.72 Bn	197.12 Bn	7.27 Bn
2	Stryker	126.42 Bn	122.94 Bn	4.50 Bn
3	Medtronic	119.75 Bn	110.53 Bn	6.41 Bn
4	Boston Scientific	74.13 Bn	73.60 Bn	3.85 Bn
5	Edwards Lifesciences	51.78 Bn	47.53 Bn	1.35 Bn
6	Dexcom	35.29 Bn	33.34 Bn	830.00 Mn
7	GE HealthCare Technologies	33.95 Bn	31.85 Bn	2.18 Bn
8	Koninklijke Philips	26.22 Bn	22.90 Bn	4.55 Bn
9	Steris	23.21 Bn	22.73 Bn	684.20 Mn
10	Biomerica	4.85 Mn	3.51 Mn	-44,000.00

Download Data